Nektar Therapeutics logo
Nektar Therapeutics NKTR
$ 56.91 -1.36%

Annual report 2023
added 03-05-2024

report update icon

Nektar Therapeutics Financial Statements 2011-2025 | NKTR

Annual Financial Statements Nektar Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

167 M 260 M 2.04 B 3.52 B 3.55 B 7.31 B 12.9 B 1.64 B 1.81 B 1.86 B 1.62 B 976 M 721 M

Shares

190 M 187 M 183 M 179 M 175 M 170 M 156 M 140 M 132 M 127 M 116 M 115 M 113 M

Historical Prices

0.88 1.39 11.1 19.7 19.9 42.3 83.6 12.1 13.6 14.6 13.6 8.57 6.25

Net Income

-276 M -368 M -524 M -444 M -441 M 681 M -96.7 M -154 M -81.2 M -53.9 M -162 M -172 M -134 M

Revenue

90.1 M 92.1 M 102 M 153 M 115 M 1.19 B 308 M 165 M 231 M 201 M 149 M 81.2 M 71.5 M

Cost of Revenue

33.8 M 21.6 M 24.9 M 19.5 M 21.4 M 24.4 M 30.5 M 30.2 M - - - - -

Gross Profit

- - - - 93.2 M 1.17 B 277 M 135 M 197 M 172 M 110 M 50.8 M 49.6 M

Operating Income

-264 M -376 M -446 M -425 M -440 M 688 M -59.6 M -113 M -29.4 M -16.5 M -120 M -141 M -124 M

Interest Expense

-6.25 M -116 K -162 K 6.85 M 21.3 M 21.6 M 22.1 M 22.5 M 18.3 M 17.9 M 18.5 M 15.5 M 10.2 M

EBITDA

-257 M -364 M -433 M -413 M -427 M 699 M -28.9 M -97.5 M -16.5 M -3.56 M -106 M -125 M -109 M

Operating Expenses

- - - - 533 M 481 M 321 M 248 M 226 M 189 M 231 M 190 M 174 M

General and Administrative Expenses

77.4 M 92.3 M 123 M 105 M 98.7 M 81.4 M 52.4 M 44.3 M 43.3 M 40.9 M 40.5 M 41.6 M 46.8 M

All numbers in USD currency

Quarterly Income Statement Nektar Therapeutics

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 188 M - 186 M 185 M 184 M 183 M 181 M 180 M 179 M 178 M 177 M 177 M 175 M 175 M 174 M 174 M 173 M 171 M 161 M 160 M 156 M 155 M 154 M 153 M 137 M 136 M 136 M 135 M 133 M 132 M 131 M 131 M 128 M 127 M 124 M 116 M 116 M 116 M 115 M 115 M 115 M 115 M 115 M 114 M 114 M 114 M 114 M

Net Income

- -59 M - -90.4 M -146 M -130 M -126 M -123 M -117 M -109 M -80 M -139 M -112 M -98.6 M -110 M -120 M -98.2 M -96.1 M 971 M -95.8 M -33.8 M 60.9 M -59.9 M -63.9 M -42.2 M -43.2 M -48.6 M -19.5 M -54.1 M -8.2 M -52.7 M 33.8 M -45.7 M 70.6 M -32.6 M -46.2 M -47.7 M -16.5 M -42.7 M -55.1 M -52.9 M -43.5 M -34.3 M -41.1 M -37.5 M -24.1 M -36.4 M -36 M

Revenue

- 23.6 M - 24.8 M 25 M 24.9 M 28.3 M 23.6 M 23.5 M 30 M 48.8 M 50.6 M 33.9 M 29.2 M 23.3 M 28.2 M 39.8 M 27.8 M 1.09 B 38 M 95.5 M 153 M 34.6 M 24.7 M 37.4 M 36.3 M 32.8 M 58.9 M 39.4 M 60 M 22.7 M 109 M 19.6 M 133 M 28.5 M 19.8 M 31.1 M 60.9 M 33.9 M 23 M 21.1 M 18.4 M 23.7 M 17.9 M 15.8 M 27.1 M 17.3 M 11.3 M

Cost of Revenue

- 4.97 M - 5.32 M 6.16 M 5.31 M 7.67 M 5.76 M 4.32 M 5.57 M 5.77 M 3.81 M 5.99 M 4.93 M 5.02 M 5.44 M 7.46 M 4.78 M 5.52 M 6.65 M 9.75 M 5.67 M 8.99 M 6.13 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 623 K 2.64 M 501 K -789 K

Operating Income

- -54.3 M - -117 M -113 M -114 M -110 M -109 M -111 M -103 M -77.7 M -134 M -110 M -98.7 M -111 M -121 M -100 M -98.6 M 974 M -86.7 M -24 M 69.5 M -50.7 M -54.4 M -32.1 M -32.9 M -38.3 M -9.48 M -29.4 M 419 K -43.5 M 43 M -37.5 M 80.3 M -22.9 M -36.4 M -35.9 M -6.52 M -32.6 M -45.1 M -43.4 M -32.9 M -27 M -37.9 M -34.5 M -21.3 M -34.3 M -33.9 M

Interest Expense

- 2.05 M - 395 K - 131 K - - - - 647 K 6.2 M - 5.42 M 5.23 M 5.23 M - 5.44 M 5.38 M 5.34 M - 5.54 M 5.51 M 5.4 M - 5.61 M 5.63 M 5.68 M - 4.2 M 4.12 M 4.17 M - 4.39 M 4.49 M 4.53 M - 4.59 M 4.66 M 4.64 M - 5.7 M 2.56 M 2.55 M -2.52 M 2.54 M 2.57 M 2.58 M

EBITDA

- -44.5 M - -113 M -113 M -103 M -110 M -106 M -111 M -92.1 M -70 M -129 M -110 M -89.2 M -105 M -118 M -100 M -90.8 M 979 M -84.2 M -24 M 81.6 M -42.4 M -50.4 M -32.1 M -21.4 M -30.7 M -5.77 M -29.4 M 9.53 M -37.6 M 46 M -37.5 M 90.1 M -16.4 M -33.1 M -35.9 M 4.36 M -25.3 M -41.5 M -43.4 M -22.1 M -20 M -34.4 M -34.5 M -9.91 M -26.6 M -30 M

General and Administrative Expenses

- 22.5 M - 27.3 M - 29.5 M 29.6 M 31.7 M - 27 M 24.3 M 26.2 M - 24 M 22.6 M 25 M - 18.7 M 20.3 M 18.7 M - 12.1 M 16 M 12 M - 10.3 M 11 M 10.2 M - 9.54 M 10.2 M 10.3 M - 9.13 M 9.62 M 9.93 M - 10.6 M 9.23 M 10.8 M - 10.1 M 10.3 M 10.4 M 11.5 M 12.4 M 11.2 M 11.7 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Nektar Therapeutics NKTR
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Nektar Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.56 -2.47 % $ 1.05 B canadaCanada
AC Immune SA AC Immune SA
ACIU
$ 2.81 -2.43 % $ 229 M schweizSchweiz
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 2.99 2.75 % $ 39.4 K usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.81 -1.33 % $ 103 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 11.96 0.17 % $ 3.7 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
argenx SE argenx SE
ARGX
$ 898.63 -1.89 % $ 25 B niderlandNiderland
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 5.91 1.55 % $ 213 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 4.68 -2.2 % $ 92.8 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 205.89 -1.29 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.48 1.45 % $ 8.37 B australiaAustralia
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
AbbVie AbbVie
ABBV
$ 225.34 -1.46 % $ 399 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.29 0.95 % $ 908 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 15.35 -12.11 % $ 2.26 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Biogen Biogen
BIIB
$ 182.33 0.19 % $ 26.5 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 27.55 -4.72 % $ 2.27 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 53.06 -1.41 % $ 10.1 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.0 - $ 27.2 B germanyGermany
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 9.36 -2.65 % $ 605 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA